Université Côte d'Azur, CNRS, INSERM, iBV, 06107 Nice, France.
Int J Mol Sci. 2020 Dec 11;21(24):9436. doi: 10.3390/ijms21249436.
Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor family. They are ligand-activated transcription factors and exist in three different isoforms, PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3). PPARs regulate a variety of functions, including glucose and lipid homeostasis, inflammation, and development. They exhibit tissue and cell type-specific expression patterns and functions. Besides the established notion of the therapeutic potential of PPAR agonists for the treatment of glucose and lipid disorders, more recent data propose specific PPAR ligands as potential therapies for cardiovascular diseases. In this review, we focus on the knowledge of PPAR function in myocardial infarction, a severe pathological condition for which therapeutic use of PPAR modulation has been suggested.
过氧化物酶体增殖物激活受体（PPARs）属于核激素受体家族。它们是配体激活的转录因子，存在三种不同的亚型，PPARα（NR1C1）、PPARβ/δ（NR1C2）和 PPARγ（NR1C3）。PPARs 调节多种功能，包括葡萄糖和脂质稳态、炎症和发育。它们表现出组织和细胞类型特异性的表达模式和功能。除了 PPAR 激动剂治疗葡萄糖和脂质紊乱的治疗潜力的既定概念外，最近的数据还提出了特定的 PPAR 配体作为心血管疾病的潜在治疗方法。在这篇综述中，我们重点介绍了 PPAR 在心肌梗死中的功能知识，心肌梗死是一种严重的病理状况，已经提出了使用 PPAR 调节来治疗。
